CN Patent

CN106562962A — 用于治疗眼部水肿、新血管形成及相关疾病的组合物和方法

Assigned to Akebia Therapeutics Inc · Expires 2017-04-19 · 9y expired

What this patent protects

本发明公开了用于治疗眼部疾病或病况——尤其是视网膜病、眼部水肿和视网膜新生血管形成——的方法。这些疾病或病况的非限制性实例包括糖尿病性黄斑水肿、年龄相关性黄斑变性(湿型)、脉络膜新生血管形成、糖尿病性视网膜病、视网膜静脉阻塞(中央或分支)、眼外伤、手术诱导性水肿、手术诱导性新生血管形成、黄斑囊样水肿、眼缺血综合征、葡萄膜炎等。

USPTO Abstract

本发明公开了用于治疗眼部疾病或病况——尤其是视网膜病、眼部水肿和视网膜新生血管形成——的方法。这些疾病或病况的非限制性实例包括糖尿病性黄斑水肿、年龄相关性黄斑变性(湿型)、脉络膜新生血管形成、糖尿病性视网膜病、视网膜静脉阻塞(中央或分支)、眼外伤、手术诱导性水肿、手术诱导性新生血管形成、黄斑囊样水肿、眼缺血综合征、葡萄膜炎等。

Drugs covered by this patent

Patent Metadata

Patent number
CN106562962A
Jurisdiction
CN
Classification
—
Expires
2017-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Akebia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.